Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bergophor futtermittelfabrik dr. berger gmbh & co. kg, kronacher str. 13, 95326 kulmbach, vokietija - kalcio ir magnio oksidas / dolomitinės kalkės; kalcio ir magnio oksidas / dolomitinės kalkės - veikliosios medžiagos cas nr.: 37247-91-9, eb nr.: 253-425-0, veikliosios medžiagos pavadinimas: kalcio ir magnio oksidas / dolomitinės kalkės, koncentracija: 15% , veiklioji; veikliosios medžiagos cas nr.: 37247-91-9, eb nr.: 253-425-0, veikliosios medžiagos pavadinimas: kalcio ir magnio oksidas / dolomitinės kalkės, koncentracija: 15% , veiklioji - veterinarinė higiena

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bergophor futtermittelfabrik dr. berger gmbh & co. kg, kronacher str. 13, 95326 kulmbach, vokietija. - kalcio ir magnio oksidas / dolomitinės kalkės - veikliosios medžiagos cas nr.: 37247-91-9, eb nr.: 253-425-0, veikliosios medžiagos pavadinimas: kalcio ir magnio oksidas / dolomitinės kalkės, koncentracija: 7% , veiklioji - veterinarinė higiena

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bergophor futtermittelfabrik dr. berger gmbh & co. kg, kronacher str. 13, 95326 kulmbach, vokietija. - kalcio ir magnio oksidas / dolomitinės kalkės - veikliosios medžiagos cas nr.: 37247-91-9, eb nr.: 253-425-0, veikliosios medžiagos pavadinimas: kalcio ir magnio oksidas / dolomitinės kalkės, koncentracija: 7% , veiklioji - veterinarinė higiena

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatos navikai - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Lietuva - lietuvių - Adama

adama - koncentruota suspensija - azoksitrobinas + ciprokonazolas - fungicidai

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

substipharm - prasugrelis - acute coronary syndrome; angina, unstable; myocardial infarction - antitromboziniai vaistai - efient, vartojamas kartu su acetilsalicilo rūgštimi (asa), skirtas aterotrombozinių reiškinių profilaktikai ūminio koronarinio sindromo (i. nestabili krūtinės angina, miokardo infarktas su st segmento pakilimu [ua / nstemi] arba miokardo infarkto st segmento pakilimu [stemi]) atliekama pirminė ar uždelstą perkutaninė koronarinė intervencija (pki).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - antinavikiniai vaistai - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. pacientams su egfr ar Šarminiai teigiamas navikas mutacijų, taip pat turėtų būti gautas tikslinis gydymas prieš gaunant keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, plazminė ląstelė - antinavikiniai vaistai - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidų vaizdavimas - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

norbrook laboratories (ireland) limited (airija) - injekcinis tirpalas - 1 ml yra: deksametazono (natrio fosfato)–2 mg. - galvijams, arkliams, šunims ir katėms gydyti, esant šokui, kolapsui dėl kraujo apytakos sutrikimo, karščiavimui, ūmiam mastitui ir uždegimui (artritui, dermatitui). melžiamoms karvėms, sergančioms acetonemija (ketoze), gydyti.